Multiple myeloma: DNA rearrangement may predict poor outcomes
A certain type of DNA marker predicts poor outcomes in multiple myeloma, researchers at Winship Cancer Institute, Emory University have found.
The marker is a kind of rearrangement of chromosomes that is rarely tested for, but may indicate resistance to immunomodulatory drugs such as lenalidomide, which have become standard therapies in multiple myeloma.
The results are scheduled for publication in Nature Communications.
Senior author Lawrence Boise, PhD, professor and vice chair for basic research in the Department of Hematology and Medical Oncology at Winship Cancer Institute and Emory University School of Medicine, is mentioned. He is also a faculty member in the BCDB, CB and IMP programs.
Click here to view the full story in Medical Xpress.